Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Echo Therapeutics has initiated a clinical study of its Symphony transdermal continuous glucose monitoring system in patients with Type 1 and Type 2 diabetes.
Subscribe to our email newsletter
Echo’s pilot clinical study will enroll 10 patients with diabetes (either Type 1 or Type 2) and will compare data obtained from its Symphony tCGM system with both the ‘gold standard’ YSI glucose analyzer and a widely-used, commercially available ‘finger-stick’ glucometer.
The study will collect more than 900 data pairs to be used in the analyses. Reference glucose measurements will be made at 15 minute intervals for 24 hours with the study data blinded to study subjects and study personnel. The company expects to complete and announce the results of the study in the third quarter of 2008.
Echo’s Symphony tCGM system is designed to provide both diabetes and hospital patients with a reliable, needle-free, easy-to-use, affordable and comfortable-to-wear continuous glucose monitoring device.
Patrick Mooney, chairman and CEO of Echo, said: “The primary purpose of this new study is to evaluate the performance of our Symphony tCGM System with Prelude as the new skin permeation element.”